GLUE Company Profile and Key Details

Q: Who are the executives of GLUE?

Dr. Markus Warmuth M.D.Pres, Chief Executive Officer & DirectorDr. Filip Janku M.D., Ph.D.Chief Medical OfficerDr. Sharon Townson Ph.D.Chief Technology OfficerDr. Owen B. Wallace Ph.D.Chief Scientific OfficerMr. Magnus Walter DPHILSenior Vice President of Chemical Sciences & Process Devel.Dr. John C. Castle Ph.D.Chief Data ScientistMs. Jennifer ChampouxChief People & Operations OfficerDr. Jullian G. Jones J.D., M.B.A., Ph.D.Chief Bus. OfficerMr. Ajim A. Tamboli C.F.A.Chief Financial OfficerMr. Phil Nickson J.D., Ph.D.Gen. CounselDr. Silvia Buonamici Ph.D.Senior Vice President of Drug Discovery BiologyMr. Philip Nickson J.D., Ph.D.Gen. Counsel

NASDAQ : GLUE

Monte Rosa Therapeutics

$12.60

0.34+2.77%

At Close 4:00 PM

68.69

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Monte Rosa Therapeutics, Inc. (GLUE) stock declined over -5.63%, trading at $11.89 on NASDAQ, down from the previous close of $12.60. The stock opened at $12.60, fluctuating between $11.70 and $12.61 in the recent session.

Stock Snapshot

12.6

Prev. Close

Market Cap

11.7

Day Low

-6.79

P/E Ratio

-1.75

EPS (TTM)

-1.1

Cash Flow per Share

12.6

Open

84.48M

Number of Shares

12.606

Day High

74.77%

Free Float in %

3.15

Book Value

1.18M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 21, 2026	12.20	12.32	12.06	12.26	1.13M
Sep 18, 2026	12.57	12.64	12.02	12.13	1.6M
Sep 17, 2026	12.84	13.02	12.43	12.60	1.29M
Sep 16, 2026	12.94	13.01	12.59	12.65	1.5M
Sep 15, 2026	13.84	13.88	12.87	12.99	1.13M
Sep 14, 2026	14.35	14.38	13.38	13.90	1.75M
Sep 11, 2026	14.24	14.74	13.88	14.07	1.17M
Sep 10, 2026	14.21	14.34	13.83	14.32	1.06M
Sep 09, 2026	14.28	14.87	14.13	14.26	1.15M
Sep 08, 2026	13.55	14.29	13.44	14.27	1.2M
Sep 04, 2026	14.12	14.31	13.79	13.84	804.58K
Sep 03, 2026	14.50	14.59	14.06	14.38	672.63K
Sep 02, 2026	14.38	15.00	13.81	14.22	1.53M
Sep 01, 2026	13.81	14.32	13.71	14.31	796.26K
Aug 31, 2026	13.39	14.11	13.12	13.94	1.11M
Aug 28, 2026	14.29	14.30	13.37	13.38	884.55K
Aug 27, 2026	14.28	14.57	14.19	14.32	1.08M
Aug 26, 2026	14.44	14.62	14.10	14.38	992.7K
Aug 25, 2026	14.06	14.84	14.00	14.56	1.1M
Aug 24, 2026	14.03	14.29	13.29	13.78	2M

Contact Details

Boston, MA 02118

United States

https://www.monterosatx.com 617 949 2643

About Company

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Stock Peers

ARGX

-24.41-2.47%

argenx SE$963.79 REGN

5.73+0.72%

Regeneron Pharmaceuticals, Inc.$803.90 MDGL

-3.13-0.60%

Madrigal Pharmaceuticals, Inc.$518.83 VRTX

4.27+0.84%

Vertex Pharmaceuticals Incorporated$514.99 UTHR

4.49+0.91%

United Therapeutics Corporation$497.59 ONC

2.41+0.66%

BeOne Medicines AG$368.08 KRYS

17.03+5.10%

Krystal Biotech, Inc.$350.88 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

1.78+0.60%

Praxis Precision Medicines, Inc.$300.65 LGND

8.43+2.91%

Ligand Pharmaceuticals Incorporated$298.50

Frequently Asked Questions

What is the current Monte Rosa Therapeutics, Inc. (GLUE) stock price?

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) stock price is $11.89 in the last trading session. During the trading session, GLUE stock reached the peak price of $12.61 while $11.70 was the lowest point it dropped to. The percentage change in GLUE stock occurred in the recent session was -5.63% while the dollar amount for the price change in GLUE stock was - $0.71.

GLUE's industry and sector of operation?

The NASDAQ listed GLUE is part of Biotechnology industry that operates in the broader Healthcare sector. Monte Rosa Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GLUE?

Dr. Markus Warmuth M.D.
Pres, Chief Executive Officer & Director
Dr. Filip Janku M.D., Ph.D.
Chief Medical Officer
Dr. Sharon Townson Ph.D.
Chief Technology Officer
Dr. Owen B. Wallace Ph.D.
Chief Scientific Officer
Mr. Magnus Walter DPHIL
Senior Vice President of Chemical Sciences & Process Devel.
Dr. John C. Castle Ph.D.
Chief Data Scientist
Ms. Jennifer Champoux
Chief People & Operations Officer
Dr. Jullian G. Jones J.D., M.B.A., Ph.D.
Chief Bus. Officer
Mr. Ajim A. Tamboli C.F.A.
Chief Financial Officer
Mr. Phil Nickson J.D., Ph.D.
Gen. Counsel
Dr. Silvia Buonamici Ph.D.
Senior Vice President of Drug Discovery Biology
Mr. Philip Nickson J.D., Ph.D.
Gen. Counsel

How GLUE did perform over past 52-week?

GLUE's closing price is 101.6% higher than its 52-week low of $6.37 where as its distance from 52-week high of $25.77 is -51.11%.

How many employees does GLUE have?

Number of GLUE employees currently stands at 173.

Link for GLUE official website?

Official Website of GLUE is: https://www.monterosatx.com

How do I contact GLUE?

GLUE could be contacted at phone 617 949 2643 and can also be accessed through its website. GLUE operates from 321 Harrison Avenue, Boston, MA 02118, United States.

How many shares of GLUE are traded daily?

GLUE stock volume for the day was 1.18M shares. The average number of GLUE shares traded daily for last 3 months was 1.43M.

What is the market cap of GLUE currently?

The market value of GLUE currently stands at $1.00B with its latest stock price at $11.89 and 84.48M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	173
Beta	1.5
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	173
Beta	1.5
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GLUE Company Profile and Key Details

Monte Rosa Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways